Global Therapeutic Report on Erythropoietin Stimulating Agents [2015]

1
Global Therapeutic Report on Erythropoietin
Stimulating Agents 2015
2
Summary
The global market for erythropoietin stimulating
agents (ESAs) will grow from nearly 7.2 billion
in 2015 to nearly 7.3 billion by 2020 with a
compound annual growth rate (CAGR) of 0.2 for
the period 2015-2020. This report provides -An
overview of the global markets and therapeutic
applications for erythropoietin stimulating
agents (ESAs). -Analyses of U.S. as well as
international market trends, with data from 2014,
2015, and projections of compound annual growth
rates (CAGRs) through 2020. -Coverage of the
market in value terms broken down by major types
of erythropoietin, by major regions, and by
applications.
3
INTRODUCTION The global market for
erythropoietin drug can be broadly classified
into two segments biologics and
biosimilars. The major types of biologic
erythropoietin drugs based on different
biological properties are epoetin-alfa,
epoetin-beta, darbepoetin-alfa and
epoetin-theta. The major types of biosimilar
erythropoietin drug based on the different
biological properties are epoetin-zeta,
epoetin-omega, epoetin-lambda and
epoetin-delta. The global erythropoietin
biologics drug market has been growing in terms
of value from the past 15 years in pace with the
increasing prevalence of chronic kidney diseases
throughout the world, however the market is
expected to see decline in the forecast period
due to expiry of major patented drugs in the U.S.
4

The global erythropoietin biosimilars drug market
has been growing rapidly in the last decade
years, primarily due to the patent expiry of
major erythropoietin biologic drug in European
market and demand for cheaper priced
erythropoietin drugs in the Asia-Pacific, South
America, Middle-east and African market. The
study covered in this report has been conducted
to analyze and quantify the emerging market
opportunities for erythropoietin drug, as well as
to highlight the key current research efforts
that are driving erythropoietin drug into new
applications. In addition, major players of the
erythropoietin drug, along with their upcoming
and anticipated erythropoietin-related products
are analyzed to demonstrate how these advances
might impact global erythropoietin drug
market. The application of erythropoietin drug
is divided broadly into three types chronic
kidney diseases oncology diseases and other
applications such as treatment of anemia in HIV
patients. The key drivers for the erythropoietin
drug market are increasing case of chronic
disease and increasing prevalence of cancer.
5

Amgen Inc., Hoffmann-La Roche and Johnson
Johnson are some of the key players of biologics
erythropoietin drug market. Sandoz (subsidiary of
Novartis International AG), Hospira (subsidiary
of Pfizer Inc.), 3SBio, BioSidus and Teva
Pharmaceutical Industries Ltd. are some of the
major players of biosimilar erythropoietin drugs
market. The market for erythropoietin in
Asia-Pacific and South America is expected to
grow at the fastest rate compared to other global
markets, which are expected to decline. The
entrant of erythropoietin biosimilars drugs in
Europe and the U.S. will create a huge impact
during the forecast period, resulting in a
decline in the global erythropoietin drug
market. This report also highlights the supplier
landscape with a focus on major companies, with
detailed profiles given.
6

STUDY GOALS AND OBJECTIVES The goal of this
report is to provide an up-to-date analysis of
recent developments and current trends in the
global erythropoietin drug market. The objective
of this type of systematic research is to
quantify the projected impact of both internal
and external forces that are affecting the global
erythropoietin drug market today and that will
affect the industry for the next several years.
Factors involved in driving product demand within
this vast untapped market will be explored in
conjunction with trends, potential sales and
forecasts for various market sectors. In
addition, major players closely involved in the
production of these erythropoietin drugs, as well
as their upcoming and anticipated products
resulting from further research and development
will be analyzed to demonstrate how these
advances might influence the existing
erythropoietin drugs market.
7

REASONS FOR DOING THE STUDY Increasing cases of
chronic kidney diseases, oncology diseases and
anemia in HIV patients across regions and the
expiry of Epogens patent in 2015, and upcoming
patent expiry of Aranesp in Europe is expected to
increase the demand for the global erythropoietin
biosimilar drug market. SCOPE OF REPORT The
scope of this report is broad and covers
erythropoietin drug used globally in various
types of applications. The market is broken down
in terms of the various types of erythropoietin
drug by region and by applications. Revenue
forecasts from 2015 to 2020 are given for
erythropoietin drug, with its applications and
regional markets. The report also includes a
discussion of the major players in each of the
regional markets for erythropoietin drug.
8

INTENDED AUDIENCE This report is intended
especially for developers, as well as consumers
with a vital interest in erythropoietin drug and
its application. In addition, because of this
reports business focus, it will be useful to
sales executives and business managers as an
up-to-date guide that includes challenges,
drivers and trends that are expected to be
significant factors in the current and future
markets. The report should also be of interest
to those in industries such as erythropoietin
drug raw materials (manufacturers and suppliers),
healthcare consulting companies, laboratory
equipment manufacturers and pharmaceutical
manufacturers.
9

INFORMATION SOURCES The findings and conclusions
of this report are based on information gathered
from a variety of primary and secondary sources.
Sources of information included industry
association data and interviews conducted with
erythropoietin drug companies. In addition, other
secondary sources were consulted for the report,
such as the Internet, industry journals and
publications, product literature, white papers
and technical journals, and financial reports
from industry suppliers. The base year for
analysis and projection is 2014. With 2014 as a
baseline, market projections were developed for
2015 to 2020. These projections are based on a
consensus among the primary contacts, combined
with our understanding of the key market drivers
and their impact from historical and analytical
perspectives.
10

RESEARCH METHODOLOGY A descriptive study has
been done for the global market for
erythropoietin drug, based on a quantitative and
qualitative approach. This Report collects data
through a variety of primary and secondary
sources including, but not limited to, interviews
with industry vendors, white papers, business
journals, public financial proceedings and
historical market data from the Internet. The
market data are assessed and validated
considering interrelated market attributes and
the impact of global economic variables. Next,
market for each erythropoietin drug is obtained
using a bottom-up approach through extensive
research by region and application of these
drugs. Finally, the global market is obtained by
adding all the erythropoietin drugs by region and
application.
11
Table of Contents
1 INTRODUCTION 2 SUMMARY 3 OVERVIEW 4 RD
DRUG PIPELINE 5 GLOBAL MARKET FORECAST FOR
ERYTHROPOIETIN DRUG 6 DRIVERS AND CHALLENGES 7
VENDOR LANDSCAPE AND COMPANY PROFILES
12
To view the full Executive Summary and Table
of Contents, please visit Global Therapeutic
Report on Erythropoietin Stimulating Agents
2015 Contact Us- Phone
91-22-27810772/73 Email id
info_at_bharatbook.com Website
www.bharatbook.com Our Blog
https//www.bharatbook.com/blog/